Update to 2007 guidance to include all types of migrants and crisis-affected populations,
including those forcibly displaced. This update stresses that migration and forced displacement
must NO T be used as an excuse to deny treatment. Clear recommendations are provided for states,
clinicians and programme managers, civil society, donors and United Nations (UN ) agencies.
2014 update to the Society guideline on adult antiretroviral therapy.
This document is provided as an information resource for all health care workers to assist in the appropriate prescribing of antibiotics.
Guideline on mental health disorders and CNS sequelae in HIV positive children and adolescents
A reference document to assist HIV nurse and doctor clinicians in managing mental health disorders
Practical guidance on the re-introduction of anti-TB drugs and ART in HIV/TB co-infected individuals presenting with DILI
Updated to include newly available drug formulations: ABC 60mg dispersible tablets and ABC (60mg) + 3TC (300mg) tablets
Update to 2007 guidelines on the prevention, diagnosis and management of cryptoccocal meningitis among HIV-infected persons
Guidance on how to switch patients from 3 separate antiretroviral (ARV) drugs to the new, single, FDC tablet containing tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV).
Recommendations for HIV resistance testing for people living with HIV in the southern African region
Guidelines include new data on antiretroviral (ARV) tolerability in the region and on new ARV drugs. Guidelines on third-line (or ‘salvage’) therapy have been expanded.
The Society develops recommendations on the management of patients in emergency situations where the provider is unable to manage per guidelines. These recommendations are written in consultation with the Society's Board of Directors and relevant advisory committees (e.g. Adult, Child and Adolescent), and are in response to acute emergency situations, such as drug stock outs.
If your facility is experiencing a lopinavir/ritonavir stock out then please follow this guidance.
Due to drug stock outs of tenofovir (TDF) and abacavir (ABC) across the country, the Society has developed some guidance for clinicians in order to ensure that no HIV infected South African currently on this treatment suffers because of these stock outs.